These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33601033)

  • 1. Letter to the editor on "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.
    Medisetty MK; Patel A; Pujari S
    Int J Infect Dis; 2021 Apr; 105():722. PubMed ID: 33601033
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.
    Udwadia ZF; Barkate H; Patil S; Rangwala S; Wu W; Caracta CF; Tandon M
    Int J Infect Dis; 2021 Apr; 105():686-687. PubMed ID: 33601032
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.
    Udwadia ZF; Singh P; Barkate H; Patil S; Rangwala S; Pendse A; Kadam J; Wu W; Caracta CF; Tandon M
    Int J Infect Dis; 2021 Feb; 103():62-71. PubMed ID: 33212256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
    McCullough PA
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32967849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.
    Fu D; Cao R; Zhao L; Li W; Zhong W; Wen J
    Crit Care; 2020 Sep; 24(1):578. PubMed ID: 32977854
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients.
    Chen PJ; Chao CM; Lai CC
    J Infect; 2021 May; 82(5):186-230. PubMed ID: 33301818
    [No Abstract]   [Full Text] [Related]  

  • 7. Real-world Experience with Favipiravir for Treatment of COVID-19 among Indian Healthcare Professionals.
    Tiwaskar M; Dhar R; Talwar D; Ansari A; Lakhe M; Panchal S; Bhagat S; Patil S; Barkate H
    J Assoc Physicians India; 2022 Dec; 69(12):11-12. PubMed ID: 35057588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favipiravir and the Need for Early Ambulatory Treatment of COVID-19.
    Korman TM
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288636
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures: Potential to Target New Outbreaks.
    Zhang WF; Stephen P; Thériault JF; Wang R; Lin SX
    J Phys Chem Lett; 2020 Jun; 11(11):4430-4435. PubMed ID: 32392072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter in response to: Alamer A, Alrashed AA, Alfaifi M, et al. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis. Curr Med Res Opin. 2021;19:1-13. DOI: 10.1080/03007995.2021.1920900.
    Dhanasekaran S; Chinnairusan M; Kagithakara Vajravelu L
    Curr Med Res Opin; 2022 Mar; 38(3):355-356. PubMed ID: 34933646
    [No Abstract]   [Full Text] [Related]  

  • 11. Comment on: Favipiravir, an antiviral for COVID-19?
    Chachaima-Mar J; Pérez-Castilla J
    J Antimicrob Chemother; 2021 Jan; 76(1):279-280. PubMed ID: 32888000
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
    Hashemian SM; Khoundabi B; Velayati AA
    Int Immunopharmacol; 2022 Jan; 102():107693. PubMed ID: 34217670
    [No Abstract]   [Full Text] [Related]  

  • 13. Alectinib, COVID-19 and favipiravir.
    Mungmunpuntipantip R; Wiwanitkit V
    J Oncol Pharm Pract; 2021 Oct; 27(7):1810. PubMed ID: 34424078
    [No Abstract]   [Full Text] [Related]  

  • 14. Bilateral foot ulcers in a COVID-19 patient under favipiravir treatment.
    Hayran Y; Albayrak İD; Öcalan DT; Aktaş A
    J Cosmet Dermatol; 2021 Aug; 20(8):2390-2391. PubMed ID: 34146463
    [No Abstract]   [Full Text] [Related]  

  • 15. Favipiravir Induced Nephrotoxicity in Two Patients of COVID-19.
    Nasa P; Shrivastava P; Kulkarni A; Vijayan L; Singh A
    J Assoc Physicians India; 2021 Jan; 69(1):90. PubMed ID: 34227789
    [No Abstract]   [Full Text] [Related]  

  • 16. Favipiravir as an Antiviral Agent in Coronavirus Disease 2019 (COVID-19): Same Script, Different Cast?
    Dauby N
    Clin Infect Dis; 2021 Aug; 73(3):e847-e848. PubMed ID: 33075124
    [No Abstract]   [Full Text] [Related]  

  • 17. Hematological Malignancy Patients, COVID-19, and Favipiravir.
    Mungmunpuntipantip R; Wiwanitkit V
    Turk J Haematol; 2021 Dec; 38(4):331-332. PubMed ID: 34792305
    [No Abstract]   [Full Text] [Related]  

  • 18. Favipiravir Induced Nephrotoxicity in two Patients of COVID-19.
    Nasa P; Shrivastava PK; Kulkarni A; Vijayan L; Singh A
    J Assoc Physicians India; 2021 Jun; 69(6):11-12. PubMed ID: 34472793
    [No Abstract]   [Full Text] [Related]  

  • 19. An AGEP case due to COVİD-19 or favipiravir or enoxaparin.
    Daye M; Oltulu P
    J Cosmet Dermatol; 2022 Jan; 21(1):13-15. PubMed ID: 34826196
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.